The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sangeeta Choudhary & PACs
LOTUSEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts more than Nifty Microcap 250 and 1.5 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sangeeta Choudhary, along with three Persons Acting in Concert (PACs) — Rajiv Choudhary, Urvija Choudhary, and Rajiv S. Choudhary HUF — has acquired 4,89,171 equity shares (2.35%) of Lotus Eye Hospital and Institute Ltd through open market transactions on 18 August 2025. The combined holding of the acquirer and PACs has increased from 15,55,765 shares (7.49%) to 20,44,936 shares (9.83%) of the company's paid-up share capital. The acquirer has clarified that they are not related to the Promoters of the company. Of the total acquired, Rajiv Choudhary bought 2,97,029 shares, Urvija Choudhary bought 1,65,142 shares, and Rajiv S. Choudhary HUF bought 27,000 shares. The disclosure is filed under Regulation 29(2), which is triggered when an acquirer's cumulative purchase crosses 2% in a financial year.
A non-promoter group has raised its stake in Lotus Eye Hospital to nearly 10%, which is a notable signal of confidence from a sizeable shareholder. With combined holdings just below the 10% mark, further purchases would trigger additional disclosure obligations under SAST regulations, potentially affecting stock price volatility and investor attention.